Jefferies analyst Biren Amin sees only small risk of a clinical hold and believes approval chances are favorable for Stemline Therapeutics' SL-401 after the company confirmed a patient death due to capillary leak syndrome. The analyst is cautious, however, on the ability of the company's management to regain investor confidence given the timing of the death relative to its recent financing. The lack of disclosure highlights the inability of management to make decisions with shareholders in mind, Amin tells investors in a research note. He points out that as of 8 PM EST last night, Stemline has not returned his calls. The analyst believes the most meaningful upside to the stock would be remedies to regain investor confidence. With that in mind, he advises the company to host an investor call. To reflect increased risk, Amin cut his price target for Stemline shares to $16 from $23. The stock closed yesterday down 43%, or $4.15, to $5.60. The analyst keeps a Buy rating on the name.